Moreover, in non-small cell lung cancer (NSCLC), the commonly treatment with tyrosine kinase inhibitors (TKIs) can induce drug-tolerant persisters (DTPs) that highly express APOBEC3A, promoting genomic instability and the evolution of drug-resistant mutations. The gene discussed is APOBEC3A; the disease is non-small cell lung carcinoma.